glp 1 for mcas Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide Receptor Agonist Therapy: Report of Two Cases A newly published case series

Using PSM on age at index, BMI, metformin and statin exposure, BRCA mutation status, hormonal contraceptive use, parity, breastfeeding history, and smoking status, they identified 2 balanced cohorts: 74,354 GLP-1 RAexposed women and 74,355 controls (total n = 148,709)

The solution remains clear but the peptide is pharmacologically inactive

Any changes to antidepressant therapy should be made cautiously, with attention to mental health stability

Also, it could be affected by a poor diet, a lack of exercise, chronic diseases, a weaker immune system, infection, and even stress

Expected Benefits for Patients and the Healthcare System The GLP-1 Bridge program has the potential to deliver significant benefits for both individuals and the broader healthcare system